How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q4 Results?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development
Drug discovery, the art of identifying new molecules to develop pharmaceuticals, is a notoriously time-consuming and difficult process.…
GLP-1 drugs transforming obesity and diabetes care in San Antonio
GLP-1 medications have transformed obesity and weight management care in the U.S. and in San Antonio. And with…
Which Is the Better Stock Buy?
Eli Lilly leads the weight loss market ahead of Novo Nordisk. Eli Lilly also has a more diversified…
Takeaways on turmoil surrounding FDA fast-track drug program
WASHINGTON (AP) — A plan to slash drug review times at the Food and Drug Administration is sparking…
FDA commissioner’s drug review plan sparks alarm
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored…
Eli Lilly’s Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief
Retatrutide’s recent trial results suggest it may be even better than Eli Lilly’s already approved GLP-1 medication, tirzepatide.…
How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its…
Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk
Lawsuit alleges anti-competitive conduct designed to suppress lawful compounding pharmaceuticals and limit patient choice GILBERT, Ariz., Jan. 14,…
The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
jetcityimage / iStock Editorial via Getty Images Lilly posted 53.9% revenue growth and 480% net income growth driven…